- Conditions: Cancer Survivor; Depression; Hematopoietic/Lymphoid Cancer
Interventions: Other: questionnaire administration; Other: survey administration; Procedure: quality-of-life assessment; Other: internet-based intervention; Other: internet-based intervention
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LuAA21004; Drug: Duloxetine; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Conditions: Alcohol Abuse; Schizophrenia; Bipolar Disorder; Major Depressive Disorder
Intervention: Behavioral: Contingency Management
Sponsors: University of Washington; University of Washington
Not yet recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: ALKS 5461; Drug: Placebo
Sponsors: Alkermes; Alkermes
Recruiting - verified April 2012 - Condition: HIV
Intervention: Behavioral: Care management
Sponsors: University of Washington; University of Washington; National Institutes of Health (NIH); National Institute of Mental Health (NIMH); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting - verified January 2012 - Condition: Major Depressive Disorder
Interventions: Drug: AZD6765 iv; Drug: AZD6765 iv; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone; Drug: Vilazodone; Drug: Citalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Acute Depressive Episode
Interventions: Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Ramelteon SL; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day; Drug: desvenlafaxine succinate sustained-release 100 mg/day; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: tasimelteon; Drug: placebo
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Lurasidone 20 mg; Drug: Lurasidone 60 mg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Not yet recruiting - verified November 2011 - Condition: Depression During Pregnancy
Interventions: Behavioral: Behavioral activation psychotherapy; Other: Usual care
Sponsors: National Institute of Mental Health (NIMH); National Institute of Mental Health (NIMH); Group Health Research Institute; Kaiser Permanente Colorado Institute for Health Services Research; Kaiser Permanente; HealthPartners Research Foundation
Not yet recruiting - verified July 2011 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Escitalopram; Drug: BMS-820836 Placebo; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Condition: Treatment Outcome
Interventions: Drug: Lu AA21004; Drug: Escitalopram
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: BMS-820836; Drug: BMS-820836
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified July 2011 - Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT; Drug: Placebo + ADT
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified July 2011 - Conditions: Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
Interventions: Drug: OPC-34712 + ADT; Drug: Placebo + ADT; Drug: Placebo + ADT
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified July 2011 - Condition: Major Depressive Disorder
Interventions: Drug: PNB01 fixed dose combination of pipamperone and citalopram; Drug: Citalopram; Drug: Pipamperone
Sponsors: PharmaNeuroBoost N.V.; PharmaNeuroBoost N.V.
Recruiting - verified March 2012 - Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Duloxetine; Drug: Placebo matching with BMS-820836; Drug: BMS-820836; Drug: Duloxetine; Drug: Placebo matching with Duloxetine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Breast Cancer; Depression; Fatigue; Sleep Disorders
Interventions: Drug: metformin hydrochloride; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Bipolar
Interventions: Drug: Lurasidone; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Treatment Resistant Depression
Interventions: Drug: CX157; Drug: Placebo
Sponsors: CeNeRx BioPharma Inc.; CeNeRx BioPharma Inc.
Recruiting - verified October 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Escitalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Major Depressive Disorder (MDD)
Interventions: Drug: LY2216684; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Depression
Intervention: Other: Collaborative care
Sponsors: Seattle Children's Hospital; Seattle Children's Hospital; National Institute of Mental Health (NIMH); Group Health Cooperative; University of Washington
Recruiting - verified July 2011 - Condition: Depression
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012 - Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness TrialConditions: Posttraumatic Stress Disorder (PTSD); Depression
Interventions: Behavioral: STEPS UP; Behavioral: OUC
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine; Department of Defense; RAND; RTI International
Recruiting - verified March 2012 - Conditions: Traumatic Brain Injury; Depression
Interventions: Behavioral: In-person Cognitive Behavioral Therapy; Behavioral: Telephone Cognitive Behavioral Therapy
Sponsors: University of Washington; University of Washington; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); U.S. Department of Education
Recruiting - verified January 2012 - Conditions: Bipolar; Depression
Intervention: Drug: lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Conditions: Posttraumatic Stress Disorder; Depression
Interventions: Behavioral: Behavioral Activation treatment; Other: Usual VA Treatment for PTSD
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Conditions: Depression; Depressive Symptoms; Anxiety; Stress Disorders, Post-Traumatic; ICU Hospitalization; Care and Treatment in ICU
Interventions: Behavioral: Facilitator-Based intervention; Behavioral: Usual Care
Sponsors: University of Washington; University of Washington; National Institute of Nursing Research (NINR)
Recruiting - verified April 2012 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified February 2012


